Amylyx Reveals Interim Rare Disease Data for Withdrawn ALS Therapy

1. Amylyx Pharmaceuticals, after withdrawing its ALS drug, is now highlighting interim data for the same therapy in the context of a rare disease.
2. The data pertains to a rare neurological disorder.
3. Amylyx is exploring a new direction for the therapy in light of the ALS drug withdrawal.
4. The company is engaging with regulators about a potential path forward for the therapy in another rare disease.
5. Amylyx's stock experienced a 7% slip following the release of phase 2 rare disease data.